You're signed outSign in or to get full access.
About
Bernard Davitian is a Partner at Omega Funds, where he specializes in investments across the life sciences and biotechnology sectors, focusing on innovative therapeutics and emerging biotech companies. At Omega Funds since 2020, Bernard is responsible for identifying, evaluating, and supporting portfolio companies, and currently serves on the boards of Vanqua Bio, Aviceda Therapeutics, Lexeo Therapeutics, and Endeavor Biomedicines.
Throughout his career, Bernard has held senior leadership roles in notable organizations, including Senior Vice President and Managing Director at Sanofi Ventures, Chief Executive Officer at Neurotech Pharmaceuticals, and Chief Financial Officer at Transgene and Fovea Pharmaceuticals, where he led significant financing and M&A transactions. His expertise centers on deploying capital in biotech, pharmaceutical, and healthcare platforms, with proven success in driving exits, including multiple NASDAQ IPOs.
Bernard holds an MBA from the Wharton School at the University of Pennsylvania and a graduate degree from EMLYON Business School, underscoring his strong foundation in management and business strategy. His contributions to the industry have established him as a trans-Atlantic investor with a reputation for advancing novel therapies and scaling high-impact biomedical enterprises.
Career History
| Organization | Role | Date Range | Details |
|---|---|---|---|
| Omega Funds | Partner | Jan 2020 to Present | — |
| Aviceda Therapeutics | Board Member | Dec 2024 to Present | — |
| Vanqua Bio | Board Member | Jul 2021 to Present | — |
| Endeavor Biomedicines | Board Member | Dec 2020 to Present | — |
| Lexeo Therapeutics | Board Member | Nov 2020 to Present | — |
| Omega Funds | Partner | Jan 2020 to Present | — |
| Sanofi | Senior Vice President and Managing Director, Sanofi Ventures | Dec 2012 to Oct 2019 | — |
| Sanofi | Vice President, Deputy of Global Head, Business Development Corporate Licenses | Jan 2010 to Jan 2012 | — |
| Fovea Pharmaceuticals | Executive Vice President and Chief Financial Officer | Jan 2006 to Jan 2010 | — |
| Neurotech Pharmaceuticals | Chief Executive Officer | Jan 2001 to Jan 2006 | — |
| Fortel Group | Chief Financial Officer and Member of the Management Committee | Jan 2000 to Jan 2001 | — |
| Transgene | Chief Operating Officer and Chief Financial Officer | Jan 1995 to Jan 2000 | — |
| Institut Merieux | Corporate Chief Financial Officer | Jan 1990 to Jan 1995 | — |
| Institut Merieux | Financial Director of Pasteur Mérieux, the Main Subsidiary | Jan 1986 to Jan 1989 | — |
| Arthur Andersen | Senior Auditor | Jan 1984 to Jan 1986 | — |
| CCMC | Corporate Development Associate, Reporting Directly to the Chief Executive Officer S Advisor | Jan 1981 to Jan 1984 | — |
Education
University of Pennsylvania
Master of Business Administration
1994 — 1994
EMLYON Business School
Master of Business Administration, Management
1978 — 1981
Skills & Expertise
Others at Omega Fund Management, LLC (1)
| Name | Role | Location |
|---|---|---|
N Noelle Hutchins | Senior Associate | Boston, MA , United States |
